Some studies suggest that in cell lines such as colorectal cancer HCT116, cervical cancer HeLa, lung cancer A549, breast cancer MCF7, and osteosarcoma U2OS(24-26), wild-type p53 renders tumor cells more sensitive to PLK1 inhibitors and enhances the apoptotic effects induced by PLK1 inhibition. Here, TP53 is linked to neoplasm.